Previous 10 | Next 10 |
Citius Pharmaceuticals Completes Enrollment in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids PR Newswire Topline Results anticipated by the end of Q2 2023 CRANFORD, N.J. , April 3, 2023 /PRNewswire/ -- Citius Pharmaceuticals, I...
2023-03-30 09:29:12 ET After a 7% rise in the previous session, Citius Pharma ( NASDAQ: CTXR ) shares continued to gain in the pre-market Thursday after the company highlighted its progress on its previously announced plans to spin off oncology candidate I/ONTAK into a standal...
Citius Pharmaceuticals Advances Efforts to Spin Off Oncology Asset, I/ONTAK, into a Standalone Public Company PR Newswire CRANFORD, N.J. , March 30, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) , a late-stage biopha...
Citius Pharmaceuticals Confirms No Exposure to Silicon Valley Bank PR Newswire CRANFORD, N.J. , March 13, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) confirms that it does not hold any cash or maintain any acc...
Citius Pharmaceuticals to Participate in the 35th Annual Roth Conference PR Newswire CRANFORD, N.J. , March 8, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the de...
Summary Shares of therapy reformulator Citius Pharmaceuticals should see volatility in the ensuing months as all three of the company’s clinical programs provide catalysts. The slowly progressing Phase 3 trial for its catheter infection therapy should produce results in 2023 whil...
Summary Citius has a PDUFA target decision date of 07/28/2023 for its I/ONTAK. The planned I/ONTAK spinoff has stalled. Commercializing I/ONTAK will strain Citius' attractive low-key financial profile. A diverse group of four products in development make up Citius' bench backing...
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2023 Financial Results and Provides Business Update PR Newswire $36.9 million in cash and cash equivalents as of December 31, 2022 ; runway through February 2024 Uptick in patient recruitment for Mino-Lok&...
NEW YORK, NY / ACCESSWIRE / January 17, 2023 / Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day January Micro-Cap Conference taking place Wednesday and Thursday, January 18-19, 2023. The links can also be found at www.sidoticonference.com/events . ...
Citius Pharmaceuticals to Present at the Sidoti Micro-Cap Virtual Conference on January 18, 2023 PR Newswire CRANFORD, N.J. , Jan. 11, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical com...
News, Short Squeeze, Breakout and More Instantly...
Citius Pharmaceuticals Inc. Company Name:
CTXR Stock Symbol:
NASDAQ Market:
Citius Pharmaceuticals Inc. Website:
2024-07-18 10:20:00 ET July 18, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmaceutical compa...
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 18, 2024) - Investorideas.com , a go-to investing platform releases the second of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a late-stage biopharmaceutical c...
2024-07-17 10:10:00 ET July 17, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmaceutical compan...